Previous 10 | Next 10 |
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), triggering a royalty stream to Arbutus ...
WARMINSTER, Pa., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial results, conference call and webcast for Wednesday, N...
WARMINSTER, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James Meyers and Myrtle Potter have been appointed to the Arbutus Board of Directors, effective Oc...
Introduction Assembly Biosciences ( ASMB ) is a small-cap biotech company focused on the development of HBV therapeutics and microbiome-based therapies. The company has decidedly focused on a new and promising drug target which has already attracted many startup biotech companies and bi...
NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Arbutus Biopharma Corporation (NASDAQ:ABUS), Tata Motors Ltd (NYSE:TTM...
Argenx (NASDAQ: ARGX ) initiated with Outperform rating and $110 (51% upside) price target at Evercore ISI. More news on: Argenx SE, Elanco, KalVista Pharmaceticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
See a week over week comparison below for the following indices, equities, commodities, bonds and currencies. More news on: Youngevity International, Inc., CorMedix Inc., Pyxus International, Inc., Top stock market news, Quick stock ideas, News on the U.S. economy, Financial stocks news, H...
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / U.S. equities finished mostly lower on Tuesday as interest rate increases and rising bond yields continued to put pressure on stocks. The Dow Jones Industrial Average declined 0.21 percent to close at 26,430.57, while the S&P 500 Index decr...
Arbutus Biopharma ( ABUS -24.1% ) is down on almost triple normal volume in apparent reaction to its announced update on its hepatitis B virus (HBV) programs that includes a delay in the start of a Phase 1 clinical trial evaluating RNA-destabilizer AB-452 in order to allow for more tim...
Introduction Arbutus Biopharma ( ABUS ) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is its diverse pipeline and financial situation. The company has made great strides in deve...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
Asserts Arbutus’ Share of Patent Infringement Claims Against Moderna and Pfizer/BioNTech is Potentially Worth Billions of Dollars and Preserving that Value Should be a Key Focus Calls on Arbutus to Cease Any Further Share Issuances and Plans to Vote AGAINST Proposed Share Incre...
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage bio...
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor tar...